Advanced searches left 3/3

Ceftriaxone - Europe PMC

Summarized by Plex Scholar
Last Updated: 10 January 2023

* If you want to update the article please login/register

Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP.

When led by therapeutic findings, this research sought to determine the current efficacy of the three antibiotics, namely cefotaxime, ceftriaxone, and ciprofloxacin, for the treatment of SBP in patients with cirrhosis with ascites. Patients with liver cirrhosis with ascites, with a polymorphonuclear cell count of > 250/mm 3 were accepted. SBP-SBP patients had a total of 261 patients with cirrhosis who had SBP. Within 48 hours of admission, the majority of the patients were diagnosed with SBP within 48 hours of admission. Both the end-stage liver disease test and the SBP determination were two important factors in surviving. In addition, these antibiotics administered as a result-guided therapy were still safe as initial treatment for SBP, particularly in those with community-acquired infections.

Source link: https://europepmc.org/article/MED/36594820


Preventive ceftriaxone in patients at high risk of stroke-associated pneumonia. A post-hoc analysis of the PASS trial.

Background Infections complicate the acute phase of stroke in one third of patients, and pneumonia in particular is correlated with an elevated risk of death or dependency. In randomized studies of stroke patients, preventive antibiotics reduced overall infections but did not reduce pneumonia or improve outcomes, but did not reduce pneumonia or improve outcomes. Methods PASS was a multicentre phase 3 trial in acute stroke patients who were randomized to preventive ceftriaxone for four days in 24 hours or standard care. The following patients were divided into three groups based on the ISAN risk score for pneumonia: low, medium, and high for this review: low, medium, and high. Patients treated with ceftriaxone or standard care exhibited an elevated risk of pneumonia with the ISAN score. Conclusions This post-hoc review of PASS revealed higher incidences of pneumonia in acute stroke patients with an ISAN score of u226515, as well as asthmatics with elevated ISAN scores.

Source link: https://europepmc.org/article/MED/36584124


Highly selective and sensitive determination of ceftriaxone sodium using nitrogen-rich carbon dots based on ratiometric fluorescence.

For food safety and environmental security, a fast and sensitive determination of ceftriaxone trace residues is of utmost importance. The functional surfaces of indole-derived carbon dots containing nitrogen and carbon groups can be specifically linked to CTR by electrostatic forces, resulting in a impeded conjugation process and premature deprotonation of the amine on the pyrrole ring, resulting in a distinct pattern in fluorescence and absorption wavelength and intensity.

Source link: https://europepmc.org/article/MED/36580812


Haematological and hepatic adverse effects of ceftriaxone in ambulatory care: a dual-centre retrospective observational analysis of standard vs high dose.

Background: The European Committee on Antimicrobial Susceptibility Testing results for methicillin-susceptible Staphylococcus aureus treatment with ceftriaxone are based on a higher dose rather than standard dose posology. We measured the incidence of neutropenia, thrombocytopenia, and elevated liver enzymes in adult patients with high dose ceftriaxone. In the 2 g and 4 g groups respectively, the time to neutropenia was 12 and 17 days from birth. In the 2 g group, thrombocytopenia was present in 0/47, compared to 3/39 in the 4 g group. In the 4 g group, the time to thrombocytopenia was 7 days. Conclusions: With a 4 g daily dose of ceftriaxone, the adverse effects were not present in an OPAT population. Despite dosing, however, complete blood pressure in patients receiving prolonged ceftriaxone was apparent, prompting the appreciable-monitoring of liver function and full blood count in patients receiving prolonged ceftriaxone.

Source link: https://europepmc.org/article/MED/36566229


Evolution of Ceftriaxone Resistance of Penicillin-Binding Proteins 2 Revealed by Molecular Modeling

Ceftriaxone is the only drug currently used to treat gonorrhea, and recent rise in PBP2 resistance to this antibiotic is a significant threat to human health. By ceftriaxone, we find mechanistic facets of PBP2 inhibition from the wild-type FA19 strain and mutant 35/02 and H041 strains of Neisseria Gonorrhoeae. The Dynamic behavior of ES complexes is investigated by using geometry and electron density measurements, such as Fukui electrophilicity index and Laplacian of electron density maps. Thus, we can explain that the genetic strains' decline in the second-order rate constant of acylation in PBP2 is due to both a decrease in the acylation rate constant k2 and an increase in the dissociation constant KS.

Source link: https://europepmc.org/article/MED/PMC9820184


Evolution of Ceftriaxone Resistance of Penicillin-Binding Proteins 2 Revealed by Molecular Modeling.

Penicillin-binding proteins 2 are two of the most important enzymes in the bacterial cell wall's formation. Ceftriaxone is the only drug used to treat gonorrhea right now, and recent rise in PBP2 resistance to this antibiotic is a significant threat to human health. The inhibition of PBP2 from the wild-type FA19 strain and the Neisseria Gonorrhoeae mutant 35/02 and H041 strains is shown by ceftriaxone in our research, which is based on mechanistic aspects. Using geometry and electron density measurements, such as Fukui electrophilicity index and Laplacian of electron density maps, we investigate the dynamic behavior of ES complexes. Thus, we can say that the experimentally observed decrease in the second-order rate constant of acylation in PBP2 from the mutant strains is due to both a decrease in the acylation rate constant k 2 and a rise in the dissociation constant K S.

Source link: https://europepmc.org/article/MED/36613627


Response surface modeling of ceftriaxone removal from hospital wastewater.

Antibiotic ceftriaxone removal from hospital wastewater using a combination process of electrocoagulation and adsorption was investigated herein. The implemented EC/AD hybrid treatment process revealed the electrical energy consumption of 0. 84 kWh -3 and 1. 2168 kWh -1 per cubic meter of hospital wastewater and a gram of used aluminum electrode, respectively, according to respectively. q m was found to be 111. 1 mg g -1 after the second-order kinetic model with R 2 of 0. 9514 and the Langmuir isotherm model with R 2 of 0. 973 were the best fit for the newly developed EC/AD hybrid treatment process. The CTX content of the hospital wastewater was reduced to zero after using the EC/AD hybrid process, according to the published experimental results.

Source link: https://europepmc.org/article/MED/36539635


Insights into the formation of environmentally persistent free radicals during photocatalytic degradation processes of ceftriaxone sodium by ZnO/ZnIn 2 S 4 .

A flower-like ZnO/ZnIn 2 ZnO/ZnIn 2 S 4 and traditional antibiotic ceftriaxone sodium were taken as study objects, focusing on EPFRs during degradation of CS by ZnO/ZIS and determining the degradation process in which EPFRs participated. Under the irradiation of 500 W xenon lamps, the degradation rate of 10 mg/L CS by 0. 8 g/L ZnO/ZIS decreased by 85. 3% in 150 min. Under visible light, the concentration level of EPFRs concentrated on oxygen atoms is 10 11 spin/mm 3. The electrons moved from precursor P8 and P11 to ZnO/ZnIn 2 S 4 heterojunction on ZnIn 2 S 4 side is -1. 91 eV, according to the adsorption energy of precursor P8 and P11.

Source link: https://europepmc.org/article/MED/36563725


Quality control and consistency evaluation of ceftriaxone sodium for injection.

Ceftriaxone sodium for injection is an antibiotic used medically. The quality of the generic and original raw materials' quality, as well as investigation of the manufacturing process revealed that the consistency of the ceftriaxone sodium raw material is the most significant factor affecting raw material's quality, while the ceftriaxone sodium crystallization process is the most significant factor affecting raw material's quality. The time to obtain therapeutic efficacy of the preparation could be preliminarily determined by determining the rate of salt formation and protein binding rate.

Source link: https://europepmc.org/article/MED/36519963

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions